×
Stéphane Bancel

Stéphane Bancel

CEO de Moderna
Stéphane Bancel es un ejecutivo de negocios francés. Es el director ejecutivo de la compañía farmacéutica y biotecnológica estadounidense Moderna, conocida por su vacuna COVID-19. Antes de unirse a Moderna, Bancel fue director ejecutivo de la... Wikipedia (Inglés)
Nacimiento: 20 de julio de 1972 (edad 51 años), Marsella, Francia
Educación: Escuela de negocios Harvard (1999–2000), École centrale Paris (1992–1995), Universidad de Minnesota (1994–1995) y más
Patrimonio neto: 4.3 miles de millones USD (2024)
Más preguntas
Location: Boston · 500+ connections on LinkedIn. View Stéphane Bancel's profile on LinkedIn, a professional community of 1 billion members.
Stephane Bancel de www.forbes.com
835 Stéphane Bancel on the 2024 Billionaires - Stephane Bancel is the CEO of Cambridge, Massachusetts-based biotech firm Moderna, known for its Covid-19.
Stephane Bancel de www.weforum.org
Named as an inventor on over 45 patent application filings in the field of messenger RNA technology. Recipient of honours and awards, including: best CEO for ...
Stephane Bancel de www.indigoag.com
Stéphane has served as the Chief Executive Officer of Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, since ...
Stephane Bancel de www.fiercepharma.com
12 mar 2024 · For his work in 2023, Bancel received a payout of around $17.1 million, down from the $19.4 million he collected in 2022, Moderna said in a ...
Stephane Bancel de www.flagshippioneering.com
Special Partner. Stéphane joined Flagship Pioneering in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is president and ...
Stephane Bancel de www.modernatx.com
Meet our board of directors ; Noubar Afeyan. Ph.D., Co-founder and Chairman, Moderna; CEO, Flagship Pioneering ; Stéphane Bancel. Chief Executive Officer.
Stephane Bancel de fi.edu
Stéphane Bancel, Albert Bourla, and Alex Gorsky piloted their companies, one a small biotech startup and the others huge multinational pharmaceutical firms, to ...